Sugi Predict

Sugi Predict / Compounds / SCHEMBL992319

SCHEMBL992319

SCHEMBL992319

CO[C](OC)OCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.57
▸ KMT2A Q03164 2/20 0.50
▸ CA12 O43570 2/20 0.50
▸ CA1 P00915 2/20 0.50
▸ CA2 P00918 2/20 0.50
▸ CA9 Q16790 2/20 0.50
▸ TDP1 Q9NUW8 2/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ SLC6A2 P23975 1/20 0.50
▸ SLC6A3 Q01959 1/20 0.50
▸ TSHR P16473 1/20 0.48
▸ NPC1 O15118 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ LMNA P02545 2/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ HCAR2 Q8TDS4 1/20 0.46
▸ MEN1 O00255 1/20 0.45
▸ IDO1 P14902 1/20 0.44
▸ MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28419926 0.85 ALDH1A1 (0.60) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL15094083 0.80 ALDH1A1 (0.61) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL11229650 0.78 ALDH1A1 (0.53) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL1549936 0.78 ALDH1A1 (0.64) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL7054639 0.78 ALDH1A1 (0.59) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL12872516 0.77 ALDH1A1 (0.52) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL21602399 0.77 ALDH1A1 (0.52) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL5145651 0.77 ALDH1A1 (0.62) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL6000944 0.77 ALDH1A1 (0.57) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL18427393 0.76 ALDH1A1 (0.68) ALDH1A1KMT2ACA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020247927-A1 NOVEL SYSTEMS, METHODS AND COMPOSITIONS FOR THE DIRECT SYNTHESIS OF STICKY ENDED POLYNUCLEOTIDES THE REGENTS OF THE UNIVERSITY OF COLORADO A BODY CORPORATE (US) 2020-12-10 — — WO claimed
US-20110009607-A1 METHOD FOR PREPARING DNA FRAGMENT HAVING STICKY END THE UNIVERSITY OF TOKYO (JP) 2011-01-13 — — US claimed
EP-2270142-A1 METHOD OF PREPARING DNA FRAGMENT HAVING STICKY END The University of Tokyo (JP) 2011-01-05 — — EP claimed
EP-4096657-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 — — EP disclosed
EP-4006041-A1 PRIMER, APPARATUS FOR PRODUCING DOUBLE-STRANDED DNA USING SAME, AND METHOD FOR PRODUCING DOUBLE-STRANDED DNA Japan Science and Technology Agency (JP) 2022-06-01 — — EP disclosed
EP-4006135-A1 PRIMER, DEVICE FOR PRODUCING DOUBLE-STRANDED DNA USING SAME, AND METHOD FOR PRODUCING DOUBLE-STRANDED DNA Japan Science and Technology Agency (JP) 2022-06-01 — — EP disclosed
US-20220162687-A1 NOVEL SYSTEMS, METHODS AND COMPOSITIONS FOR THE DIRECT SYNTHESIS OF STICKY ENDED POLYNUCLEOTIDES THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE 2022-05-26 — — US disclosed
CN-114302965-A Primer, double-stranded DNA production apparatus using the same, and double-stranded DNA production method 国立研究开发法人科学技术振兴机构 2022-04-08 — — CN disclosed
CN-114174509-A Primer, double-stranded DNA production apparatus using the same, and double-stranded DNA production method 国立研究开发法人科学技术振兴机构 2022-03-11 — — CN disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 — — WO disclosed
EP-3795577-A1 MODIFIED NUCLEOTIDES Illumina Cambridge Limited (GB) 2021-03-24 — — EP disclosed
US-8071739-B2 Modified nucleotides ILLUMINA CAMBRIDGE LIMITED (GB) 2011-12-06 — — US disclosed
US-20110009607-A1 METHOD FOR PREPARING DNA FRAGMENT HAVING STICKY END THE UNIVERSITY OF TOKYO (JP) 2011-01-13 — — US disclosed
EP-2270142-A1 METHOD OF PREPARING DNA FRAGMENT HAVING STICKY END The University of Tokyo (JP) 2011-01-05 — — EP disclosed
US-20100292452-A1 Modified nucleotides ILLUMINA CAMBRIDGE LTD 2010-11-18 — — US disclosed
US-7771973-B2 sequencing reactions where nucleotide or nucleoside molecules modified by reversible covalent attachment of 3'-OH blocking groups thereto, are used where blocked nucleotide or nucleoside molecules are required ILLUMINA CAMBRIDGE LIMITED (GB) 2010-08-10 — — US disclosed
US-20090325172-A1 Modified nucleotides SOLEXA LIMITED 2009-12-31 — — US disclosed
US-7541444-B2 Modified nucleotides ILLUMINA CAMBRIDGE LIMITED (GB) 2009-06-02 — — US disclosed
US-20070166705-A1 Modified nucleotides ILLUMINA CAMBRIDGE LIMITED (GB) 2007-07-19 — — US disclosed
EP-1304325-A1 5-(M-CYANOBENZYLAMINO)PYRAZOLE DERIVATIVES Sankyo Company, Limited (JP) 2003-04-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292452-A1 Modified nucleotides ADAR, NT5C2, NSUN2 ALDH1A1 2073/4885KMT2A 1035/4885CA12 2511/4885
US-20070166705-A1 Modified nucleotides NT5C2, ADAR, DUT ALDH1A1 2076/4885KMT2A 1056/4885CA12 2380/4885
US-20110009607-A1 METHOD FOR PREPARING DNA FRAGMENT HAVING STICKY END POLB, POLL, POLN ALDH1A1 2795/4885KMT2A 2229/4885CA12 4627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.